Actos and the FDA
Actos (pioglitazone) is a drug used to treat Type 2 diabetes, and sadly, it has recently been linked to an increased incidence of bladder cancer. Diabetics who have been taking Actos for more than a year have been found to have a significantly increased chance of developing bladder cancer. In June 2011, the US Food and Drug Administration (FDA) added a warning about this risk to the labels of pioglitazone-containing medications.
If you have been diagnosed with bladder cancer after using Actos to manage your Type 2 diabetes, you may be eligible for compensation. Contact the experienced Actos lawsuit attorneys of Williams Kherkher today by calling 800-641-9810 and learn what we can do to help you.
FDA Investigation of Actos
Actos became available in 1999 and was widely used. The FDA began investigating the link between Actos and bladder cancer in September 2010, using data from an ongoing 10-year study. The study later showed that after a period of 24 months, Actos users had a significant increase in the likelihood of developing bladder cancer. Actos has been taken off the shelves in France and Germany.
The FDA’s study has led the organization to urge doctors to be more careful when prescribing Actos to patients. Doctors should not prescribe Actos to people who have a family history of bladder cancer or people who presently have bladder cancer.
In 2010, over 2.3 million people filled prescriptions for pioglitazone-containing medications, more commonly known as Actos. If you or someone you know has developed bladder cancer after being prescribed Actos to treat Type 2 diabetes, you may be able to seek compensation for the costs of your treatments and other damages. The knowledgeable Actos lawyers of Williams Kherkher are here to help you fight for this compensation. Contact us at 800-641-9810 today to learn more.